About Axis Bio
Axis Bio is a preclinical CRO founded in 2013 in Northern Ireland, recognised for its scientific expertise and fully bespoke solutions in early drug discovery. The company supports clients across the UK, Europe, the Middle East and North America through a collaborative approach and customised preclinical models. In 2025, Axis Bio joined the QIMA Group, strengthening its scientific capabilities and international footprint. Its mission is to accelerate the development of new therapies while reducing risk, time and cost. Its ambition is to become a leading player in preclinical research for the benefit of human health.
Industries We Serve
- Pharmaceutical
- Biotechnolgy
- Academic research
Why working with us?
Axis Bio is trusted by academic leaders and biotech innovators for its scientific excellence, collaborative mindset, and tailored approach to preclinical research. Our clients value not only the quality of our data, but also the strength of the relationships we build and our ability to act as true scientific partners throughout their drug development journey.
- Bespoke scientific solutions tailored to each project’s unique research needs
- Recognised expertise in oncology and drug discovery with rigorous industry standards
- A collaborative, partnership-driven approach that feels like an extension of your own team
- High-quality, reliable data combined with thoughtful interpretation and strategic input
- Agile support for biotech companies and academic teams tackling complex and innovative programmes
- A strong culture of ownership and accountability, ensuring excellence in every deliverable
Therapeutical areas
- Oncology
- Immunology
- Inflammation
- Respiratory
- Metabolic disorders
- Rheumatology
Overview of Solutions
- Cell biology
- Non-GLP tolerability studies
- PK/PD and biodistribution
- Syngeneic and orthotopic cancer studies
- Humanised in vivo disease models
- Ex vivo analyses
Technology & type of analysis available
- 2D and spheroid screening assays
- Coculture assays
- Migration assays
- Multiplexed cytokine assays
- Gene knock-down and knock-out
- ELISA/Western blotting
- Real time PCR
- FACS immunophenotyping
- On-site phlebotomy
- Ex vivo blood cell assays
- Activation and Exhaustion assays
- Immune cell-mediated cancer cell killing
- Surgical tumour implantation
- In vivo disease scoring
- Metastatic and disseminated tumour models
- In vivo imaging systems
- Survival studies
- Complete Blood Counts and Blood Chemistry Assessment
- BALF analysis
- Histology
- Biomarker integration
- Development of ADA
